Home › Triple-Negative Breast Cancer › Illinois › Chicago
Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Chicago, IL
16 pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Chicago (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Nagre-recruitPhase 1
- University of Chicago Hospital, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
Nagre-recruitPhase 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Nagre-recruitPhase 3
- University of Illinois Cancer Center ( Site 0044), Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Nagre-recruitPhase 1
- Northwestern University Feinberg School of Medicine, Chicago
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Nagre-recruitPhase 3
- Northwestern Medicine, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Nagre-recruitPhase 2/3
- Local Institution - 0280, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Nagre-recruitPhase 1/2
- Northwestern University, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
Nagre-recruitPhase 1
- The University of Chicago Medical Center (UCMC), Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Nagre-recruitPhase 1
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
Study of XB010 in Subjects With Solid Tumors
Nagre-recruitPhase 1
- University of Chicago Medical Center, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Nagre-recruitPhase 1/2
- Northwestern Memorial Hospital, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Nagre-recruitPhase 2
- University of Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Nagre-recruitPhase 2
- University of Chicago Medical Center, Chicago
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Nagre-recruitPhase 1
- UChicago Medicine Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Nagre-recruitPhase 1
- University of Chicago, Chicago
Pag-aaral para sa Triple-Negative Breast Cancer sa ibang lungsod
- Houston, TX42 pag-aaral
- New York City, NY31 pag-aaral
- Nashville, TN28 pag-aaral
- Los Angeles, CA27 pag-aaral
- Boston, MA26 pag-aaral
- San Antonio, TX23 pag-aaral
- St. Louis, MO21 pag-aaral
- Arlington, VA20 pag-aaral
- Atlanta, GA20 pag-aaral
- Dallas, TX18 pag-aaral
- Columbus, OH16 pag-aaral
- Grand Rapids, MI15 pag-aaral
Iba pang pag-aaral sa Chicago
- Non-Small Cell Lung Cancer61 pag-aaral
- Kanser sa Suso59 pag-aaral
- Kanser (lahat ng uri)51 pag-aaral
- Metastatic Cancer45 pag-aaral
- Kanser sa Prostate45 pag-aaral
- Kanser sa Baga41 pag-aaral
- Obesity41 pag-aaral
- Kanser sa Ovary36 pag-aaral
- Colorectal Cancer34 pag-aaral
- Stroke34 pag-aaral
- Pagkabigo ng Puso31 pag-aaral
- Overweight29 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.